Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HARVARD BIOSCIENCE INC Director's Dealing 2019

Aug 19, 2019

34975_dirs_2019-08-19_55c3128a-f65d-4e32-ba19-6bdc8d5d7fc6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2019-08-16

Reporting Person: Green James W (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-08-16 Common Stock P 10000 $2.485 Acquired 1525404 Indirect

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $2.47 to $2.50, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (b) a deferred stock award of 202,875 restricted stock units which shall fully vest on July 8, 2020; (c) a deferred stock award of 243,072 restricted stock units which shall fully vest on July 8, 2021; (d) a deferred stock award of 418,360 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (e) a deferred stock award of 418,360 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (f) 207,637 shares of common stock beneficially owned by the Reporting Person.